- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
NTRB
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Nutriband Inc · Healthcare · Biotechnology
Latest close
2.98 USD
-4.2%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -22.2% below the Trend Line and sits at 1.4% of its 52-week range. The latest completed week returned -4.2%, after a -2.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 40d.
Setup score
23
out of 100
Latest Close
2.98 USD
24 Jul 2026
1W Return
-4.2%
latest completed week
4W Return
-2.6%
short-term follow-through
12W Return
-22.8%
quarterly tape
Trend Breadth
28.8%
15 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.2%
Latest completed week; four-week move -2.6%.
Indicator stack
16/30
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
53 relevant articles in the latest sentiment read.
Event risk
40d
Next report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -22.2% below the Trend Line and sits at 1.4% of its 52-week range. The latest completed week returned -4.2%, after a -2.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0712-week average 0.11
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.6% over four weeks, -22.8% over 12 weeks, and -65.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year15
Trend breadth28.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.68Latest activity-pressure read.
Pressure change-94.6%Four-week change in activity pressure.
Leadership-45.05Latest relative-leadership reading.
RS change9.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Jan 2026
Field coverage 82%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value48/100Relative valuation strength. Underlying universe rank 53; rank 1 is best.
Quality47/100Profitability and accounting quality. Underlying universe rank 54; rank 1 is best.
Momentum49/100Medium-term price momentum. Underlying universe rank 52; rank 1 is best.
Growth49/100Revenue and earnings growth. Underlying universe rank 52; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 20.1x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -13.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 28.4% Gross profit retained from each unit of revenue.
- Operating margin
- -447.2% Operating profit retained from revenue.
- Free-cash-flow margin
- -241.3% Free cash flow generated from revenue.
- Return on invested capital
- -272.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -24.8% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -14.6% Net share repurchases relative to market value.
- Shareholder yield
- -14.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 53 relevant articles.
6 positive · 45 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings40dNext report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-65.5%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher9 of 2616 weeks finished lower.
Best week+10.3%Week of 17 Apr.
Worst week-14.5%Week of 19 Jun.
Latest week-4.2%Week of 24 Jul.
Shape of recent returns
Strong gains6
Modest gains3
Flat weeks1
Modest losses7
Sharp losses9
Recent vol5.0%13-week weekly-return volatility.
Base vol6.4%52-week weekly-return volatility.
Up/down split19/32Count of positive and negative weeks in the 52-week window.
Average skew4.6% / -5.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape22/100
Trend, activity pressure, participation, and risk combine to a 22/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.07; No reversal markers Factors47/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 89 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 53 relevant articles.
Nutriband Inc (NTRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders50/100No recent insider transaction evidence is stored.
Earnings40dNext report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 2.98 USD | -4.2% | 3.83 USD | 4.19 USD | -0.68 | -45.05 | 51.4K | Off |
| 17 Jul 2026 | 3.11 USD | 5.1% | 3.89 USD | 4.19 USD | -0.48 | -45.00 | 82.5K | Off |
| 10 Jul 2026 | 2.96 USD | -3.3% | 3.94 USD | 4.19 USD | -0.52 | -50.66 | 60.4K | Off |
| 3 Jul 2026 | 3.06 USD | 0.0% | 4.01 USD | 4.19 USD | -0.45 | -48.96 | 63.2K | Off |
| 26 Jun 2026 | 3.06 USD | 5.5% | 4.07 USD | 4.19 USD | -0.35 | -49.67 | 85.4K | Off |
| 19 Jun 2026 | 2.90 USD | -14.5% | 4.13 USD | 4.18 USD | -0.36 | -55.18 | 56.6K | Off |
| 12 Jun 2026 | 3.39 USD | -5.3% | 4.19 USD | 4.18 USD | -0.24 | -47.14 | 48.6K | Off |
| 5 Jun 2026 | 3.58 USD | 2.6% | 4.26 USD | 4.17 USD | -0.23 | -43.64 | 47.3K | Off |
| 29 May 2026 | 3.49 USD | -4.1% | 4.35 USD | 4.16 USD | -0.20 | -48.26 | 69.6K | Off |
| 22 May 2026 | 3.64 USD | 1.1% | 4.45 USD | 4.15 USD | -0.18 | -45.09 | 42.6K | Off |
| 15 May 2026 | 3.60 USD | -4.0% | 4.57 USD | 4.14 USD | -0.15 | -45.44 | 31.3K | Off |
| 8 May 2026 | 3.75 USD | -2.8% | 4.70 USD | 4.14 USD | 0.03 | -43.76 | 83.0K | Off |
| 1 May 2026 | 3.86 USD | -3.4% | 4.82 USD | 4.13 USD | -0.01 | -39.44 | 39.8K | Off |
| 24 Apr 2026 | 4.00 USD | -7.1% | 4.94 USD | 4.12 USD | -0.10 | -36.96 | 21.5K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.